Trial Profile
A single-institution, retrospective case study evaluating response of Daratumumab and Elotuzumab in Multiple Myeloma patients in African Americans Versus Whites
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Elotuzumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Oct 2018 New trial record
- 10 Oct 2018 Primary endpoint has been met. (Overall response rate at 2 months for daratumumab and at 4 months for elotuzumab)
- 10 Oct 2018 Results published in the Cancer